Category Archives: Biotechnology and Pharmaceuticals

Numira Biosciences, Penguin Computing Partner for Cloud Pre-Clinical Imaging

Penguin Computing and Numira Biosciences announced a partnership to bring graphics-intense data on-demand to Life Sciences customers. The platform will leverage a convergence of enabling technologies from Penguin Computing’s HPC as a Service offering, POD; Numira Biosciences’ AltaPortal product; and Nvidia’s GPU technology to deliver advanced pre-clinical imaging services to researchers at pharmaceutical and biotechnology companies around the globe.

Researchers will benefit from the cutting edge graphics, GPU power, global accessibility and reliability of Penguin Computing’s HPC as a Service platform, POD. Numira’s AltaPortal product provides a secure web interface for managing projects and exploring datasets, media and documents. By leveraging POD, AltaPortal will enable researchers to interactively navigate rich 3D data from microCT scans with overlaid analytics customized to the task at hand. The data will be delivered as a media stream to the client’s web browser, eliminating the need to transfer large and potentially proprietary datasets over networks, and allowing them to be secured in a central location.

“Penguin has enjoyed steady growth in the genomics sector with its POD offering. Adding Numira’s medical imaging software and services to our POD partner portfolio will enhance our breadth in the bioinformatics market and further establish POD as a destination for that set of users” said Matt Jacobs, SVP of Corporate Development for Penguin Computing.

“At Numira we’ve built our reputation delivering rich quantitative analytics for preclinical medical imaging. With our AltaPortal web service, we’re taking it to the next level; our customers will be able to interactively explore and quantitatively assess their preclinical imaging data with our custom 3D visual analytic tools. Penguin’s POD service offers the ideal platform for our rendering-on-demand engine,” said David Weinstein, Numira’s Chief Technology Officer.


Assay Depot, AstraZeneca Launch Virtual Research Laboratory for Drug Researchers

Assay Depot Inc. today announced the launch of a virtual research laboratory. Developed in partnership with AstraZeneca, the virtual laboratory is a vendor relationship management (VRM) system that gives researchers easy access to a distributed network of thousands of research service providers located inside and outside the company.

“We brought together features of today’s favorite consumer websites to create a virtual laboratory that empowers scientists,” stated Kevin Lustig, Assay Depot’s CEO. “A small group of talented scientists can now run an entire drug discovery program, from concept to clinic, from a laptop computer.”

The private virtual laboratory (aka Research Exchange) enables researchers to search for research services and vendors, communicate with experts, purchase services, and rate and review services. In one simple and intuitive interface, scientists identify experts, initiate research collaborations, and track entire projects to completion.

Researchers can access the virtual laboratory from anywhere they access the Internet, including tablets and mobile devices. They can view their colleagues’ ratings and reviews, view past transactions and determine at a glance which vendors have current legal agreements.

“The virtual drug discovery era has arrived,” said Chris Petersen, Assay Depot’s CIO. “Enabling research scientists to access any service and any expert in just a few mouse clicks can dramatically improve productivity, reduce costs and promote innovation.”

A private virtual laboratory enables complete transparency across global research operations while retaining local control over research sourcing decisions. It simplifies legal and compliance verification, standardizes sourcing governance and serves as a versatile all-in-one platform that benefits the entire chain of pharmaceutical stakeholders, including discovery research, supply chain and consumer health.